The first tests not being conclusive, the Institut Pasteur has decided to put an end to one of its vaccine projects against Covid-19, with less effective results than expected. The vaccine used the measles vaccine as a base.
The Institut Pasteur put an end, on January 25, to the development of “one of its vaccine candidates” against Covid-19. The first trials on this vaccine developed in partnership with the Merck group (MSD) have indeed shown that it was less effective than hoped. In its press release, the American pharmaceutical group Merck explains that it is ending the development of the two vaccines it was working on, saying it wants to focus on research into treatments for the disease.
And the Pasteur Institute clarified: “The vaccine candidate was well tolerated, but the induced immune responses were found to be lower than those observed in people cured of a natural infection as well as those observed with authorized vaccines against SARS-CoV-2 / Covid-19. “
Pasteur’s vaccine used as a basis the measles vaccine, adapted to fight Covid-19. Phase 1 trials (the first stage of human trials) began last August.
Other work in progress
Pasteur said he was continuing his work on other vaccine projects against Covid-19, at a preliminary stage, however. “The first, which can be administered by the nasal route, has been developed with the biotechnology company TheraVectys, a member of the Institut Pasteur and specializing in the development of vaccines. The second is a DNA vaccine candidate, ”said Pasteur. These two projects “are now in the preclinical phase”, that is to say that no trials have yet been carried out on humans.
In addition, this judgment “does not call into question the continuation of other vaccine research projects carried out in partnership with Themis / Merck-MSD”, based on the measles vaccine, says Pasteur. According to the institute, research is underway to use this technology against other infectious diseases (Lassa fever, chikungunya).